CN Patent

CN1282242A — 多相催化蛋白酶抑制剂用作抗肿瘤剂

Assigned to Cephalon LLC · Expires 2001-01-31 · 25y expired

What this patent protects

本文涉及多相催化蛋白酶(MCP)特异性抑制剂用作肿瘤细胞程序性细胞死亡(即,编程性细胞死亡)的诱导剂,更具体地说用作抗肿瘤剂的应用方法。本发明提供了利用MCP抑制剂诱导转化细胞的编程性细胞死亡,抑制转化细胞增殖,以及抑制肿瘤生长的方法。

USPTO Abstract

本文涉及多相催化蛋白酶(MCP)特异性抑制剂用作肿瘤细胞程序性细胞死亡(即,编程性细胞死亡)的诱导剂,更具体地说用作抗肿瘤剂的应用方法。本发明提供了利用MCP抑制剂诱导转化细胞的编程性细胞死亡,抑制转化细胞增殖,以及抑制肿瘤生长的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN1282242A
Jurisdiction
CN
Classification
—
Expires
2001-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Cephalon LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.